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Abstract
Tongue	squamous	cell	carcinoma	(TSCC)	has	a	poor	prognosis	due	to	its	early	me‐
tastasis	 through	 blood	 and	 lymphatic	 vessels.	We	 undertook	 a	 systematic	 review	
to	 investigate	 the	prognostic	 significance	of	blood	microvessel	density	 (MVD)	and	
lymphatic	vessel	density	(LVD)	in	TSCC	patients.	We	carried	out	a	systematic	search	
in	Ovid	Medline,	Scopus,	and	Cochrane	libraries.	All	studies	that	evaluated	the	prog‐
nostic	significance	of	MVD/LVD	markers	in	TSCC	were	systematically	retrieved.	Our	
results	showed	that	MVD/LVD	markers,	CD31,	CD34,	CD105,	factor	VIII,	lymphatic	
vessel	endothelial	hyaluronan	receptor‐1,	and	D2‐40	were	evaluated	in	TSCC	patients	
until	28	June	2018.	Six	out	of	13	studies	reported	markers	that	were	associated	with	
poor	prognosis	in	TSCC.	Two	out	of	three	studies	suggested	that	a	high	number	of	
D2‐40+	vessels	predicated	low	overall	survival	(OS);	the	third	study	reported	that	the	
ratio	of	D2‐40+	over	factor	VIII+	vessels	is	associated	with	low	OS.	Most	of	the	other	
markers	had	controversial	results	for	prognostication.	We	found	higher	expression	of	
MVD/LVD	markers	were	commonly,	but	not	always,	associated	with	shorter	survival	
in	TSCC	patients.	It	is	therefore	not	currently	possible	to	recommend	implementation	
of	these	markers	as	reliable	prognosticators	in	clinical	practice.	More	studies	(espe‐
cially	for	D2‐40)	with	larger	patient	cohorts	are	needed.
K E Y W O R D S
biomarker,	blood	microvessel	density,	lymphatic	vessel	density,	prognosis,	tongue	squamous	
cell carcinoma
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1  | INTRODUC TION
Tongue	squamous	cell	carcinoma	(TSCC)	is	one	of	the	most	com‐
mon	 types	 of	 head	 and	 neck	 squamous	 cell	 carcinoma	 (HNSCC)	
and	 has	 an	 increasing	 incidence	 in	 many	 European	 and	 Nordic	
countries.1	Cancer	metastasis	is	the	leading	cause	of	death	in	TSCC	
patients.	Unfortunately,	the	survival	rate	has	not	significantly	im‐
proved	over	recent	decades.2	Cancer	staging	is	considered	a	vital	
tool	 in	 predicting	 the	 treatment	 and	 survival	 outcomes	of	 TSCC	
patients.3	The	TNM	classification	is	currently	the	mainstay	of	clin‐
ical	 staging	 of	 TSCC	 patients.4	 Despite	 its	 widespread	 use,	 this	
system	has	been	criticized	 for	not	considering	 the	biological	be‐
havior	and	heterogeneity	of	 individual	cancers.	For	example,	 the	
TNM	staging	scheme	shows	little	or	no	prognostic	value	 in	early	
TSCC.5,6	Therefore,	 it	 is	 important	to	supplement	the	TNM	stag‐
ing	system	with	new	histological	features	and	biomarkers.7,8	TSCC	
currently	lacks	reliable	prognosticators	that	can	predict	outcome	
and	response	to	therapy.
Angiogenesis	(new	blood	vessel	formation)	and	lymphangiogene‐
sis	(new	lymph	vessel	formation)	are	vital	processes	for	tumor	devel‐
opment	 and	propagation.9	 These	 complex	vasculature	 systems	are	
essential	not	only	for	enriching	tumor	cells	but	also	to	facilitate	the	
establishment	of	metastatic	colonies	 in	secondary	 tissues.9	Almost	
all	types	of	malignant	carcinomas	have	the	potential	to	metastasize	
to	 regional	 lymph	 nodes	 and	 distant	 tissues.10	 In	 fact,	 some	 can‐
cers	metastasize	by	utilizing	both	 the	blood	and	 lymphatic	 vessels	
simultaneously,	whereas	others,	such	as	TSCC,	prioritize	spreading	
through	lymphatic	routes	to	the	sentinel	lymph	nodes.9,11	In	this	con‐
text,	both	MVD	and	LVD	were	successfully	used	as	parameters	 to	
study	the	tumor	biology,	prognosticators,	and	therapeutic	targets	in	
several	cancers	including	HNSCC.12‐15	The	assessment	of	such	vas‐
cular	parameters	 is	often	 facilitated	by	 the	use	of	well‐established	
immunohistochemical	antibodies	(Abs).	These	Abs	include	a	variety	
of	blood	vessel	markers,	such	as	CD34,	CD31,	CD105	(endoglin),	and	
FVIII	 in	 addition	 to	markers	 for	 lymphatic	 vessels,	 such	 as	 D2‐40	
(podoplanin)	and	LYVE‐1.
Assessment	of	prognostic	parameters	 at	 the	 time	of	diagnosis	
is	 essential	 for	 proper	 risk	 stratification	 of	 cancer	 patients.16 To 
the	best	of	our	knowledge,	there	are	currently	no	biomarkers	that	
reliably	 correlate	with	 the	 prognosis	 and	 therapeutic	 response	 in	
TSCC	 patients.	 Several	 studies	 have	 investigated	 the	 potential	 of	
the	 tumor	 vasculature	 as	 a	 prognosticator	 in	 TSCC.	 Therefore,	 in	
this	study	we	sought	to	systematically	review	the	current	evidence	
of	 the	 prognostic	 value	 of	 blood	 and	 lymphatic	 vessel	markers	 in	
patients	with	TSCC.
2  | METHODS
2.1 | Protocol and registration
This	 review	 study	was	 registered	 at	 the	 international	 prospective	
register	 of	 systematic	 reviews	 PROSPERO	 (https	://www.crd.york.
ac.uk/prosp	ero/)	with	the	registration	number	CRD42019115141.
2.2 | Search strategy
We	 carried	 out	 a	 comprehensive	 search	 in	 3	 electronic	 databases	
(Ovid	Medline,	Scopus,	and	Cochrane	Library)	combining	the	following	
search	terms:	(“tongue”)	AND	(“cancer”	OR	“neoplasm”	OR	“carcinoma”	
OR	“squamous	cell	carcinoma”	OR	“tumor*”)	AND	(“angiogenesis”	OR	
“blood	 vessel”	 OR	 “lymphangiogenesis”	 OR	 “lymphatic	 vessel”	 OR	
“lymph	vessel”	OR	 “cd31*”	OR	 “cd34*”	OR	 “cd45*”	OR	 “icam‐1*”	OR	
“cd54*”	OR	“lyve‐1*”	OR	“tie‐2*”	OR	“tek*”	OR	“vcam‐1*”	OR	“cd106*”	
OR	“ve	cadherin”	OR	“vegf‐r2”	OR	“vascular	endothelial	growth	factor	
receptor	2”	OR	“FVIII‐RA”	OR	“FVIII”	OR	“factor	8”	OR	“von	willebrand	
factor”	OR	“vwf”	OR	“erg”	OR	“vegf”	OR	“d2‐40”	OR	“podoplanin”	OR	
“prospero‐related	homeobox‐1”	OR	“vegf‐r3”	OR	“peripheral	node	ad‐
dressin	antibody”).	Both	the	abbreviated	and	full	name	of	each	vessel	
marker	were	used.
The	 results	 obtained	 with	 these	 search	 terms	 were	 gathered	
together	 in	RefWorks.	The	article	 search	was	undertaken	with	no	
time/language	restrictions	on	28	June	2018	and	therefore	articles	
published	 after	 that	 date	 were	 not	 considered.	 The	 PRISMA	was	
used	to	illustrate	the	results	in	a	flowchart	of	search.17	In	the	Ovid	
Medline	advanced	search,	the	set	search	fields	were:	abstract,	origi‐
nal	title,	subject	heading,	keyword.
If	 the	 same	patient	 cohort	was	 involved	 in	multiple	publica‐
tions,	only	the	most	recent	study	was	included.	Two	authors	(R.A.	
and	M.K.)	independently	screened	all	article	titles	and	abstracts.	
In	the	screening,	duplicates	were	discarded	and	articles	were	ver‐
ified	to	meet	the	inclusion	criteria	listed	in	Table	S1.	Articles	not	
passing	the	inclusion	criteria	were	excluded	during	the	screening	
process.
2.3 | Data extraction
The	 following	 information	was	extracted	 from	each	 study:	 (i)	 basic	
article	information,	including	first	author,	publication	year,	study	pe‐
riod,	 and	 follow‐up	duration;	 (ii)	 patient	and	 tumor	 information,	 in‐
cluding	the	number	and	location	of	patients,	mean	age,	gender,	tumor	
site	and	size,	disease	stage,	number	of	patients	who	underwent	im‐
munohistochemical	 staining	 and	 the	 number	with	 positive	 staining	
results,	name	and	source	of	the	Ab,	Ab	dilution,	and	sample	preser‐
vation	(paraffin‐embedded	or	frozen);	(iii)	survival	analysis,	including	
type	of	 survival,	 end‐point,	Kaplan‐Meier	 curves	and	 statistical	 re‐
sults	 (estimated	HR,	95%	CI,	and	P	values);	and	(iv)	variables	meas‐
uring	vessel	marker	expression,	 including	 lymphatic	or	blood	vessel	
density,	location	of	the	staining,	and	cut‐off	value	as	a	definition	for	
positive	expression.
2.4 | Quality and risk of bias assessment
We	 assessed	 the	 reporting	 quality	 of	 the	 eligible	 studies	 accord‐
ing	 to	 the	 REMARK	 guidelines,	 a	 20‐item	 checklist	 aimed	 at	 en‐
suring	 the	 quality	 and	 reproducibility	 of	 the	 reported	 data.18 The 
selected	and	applied	REMARK	guidelines	of	the	eligible	studies	are	
listed	in	Table	S2.	For	the	risk	of	bias,	two	authors	(R.A.	and	M.K.)	
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answered	 10	 questions	 for	 each	 study	 using	 MAStARI.	 Answers	
were	described	as	Y	 for	 “yes,”	N	 for	 “no,”	U	 for	 “unclear,”	 and	NA	
for	“not	applicable”.	The	risk	of	bias	was	categorized	as	high	when	
the	study	reached	up	to	49%	of	a	“yes”	score,	moderate	when	the	
study	reached	a	50%‐69%	of	a	“yes”	score,	and	low	when	the	study	
reached	more	than	70%	of	a	“yes”	score.
3  | RESULTS
3.1 | Search results
We	 found	 a	 total	 of	 515	 articles	 from	 3	 electronic	 databases	
(332	 from	 Ovid	 Medline,	 142	 from	 Scopus,	 and	 41	 from	 the	
Cochrane	 Library)	 and	 1	 from	 a	 previous	 search.	 After	 screen‐
ing	 titles	 and	 abstracts,	 36	 articles	 were	 subsequently	 verified	
for	eligibility	(Figure	1).	Of	these,	only	13	articles	met	the	inclu‐
sion	criteria	and	were	therefore	included	in	this	review.	In	these	
studies,	samples	from	patients	with	TSCC	were	used	to	evaluate	
the	following	vessel	markers:	CD34,	CD31,	CD105,	FVIII,	D2‐40,	
and	LYVE‐1.	For	MVD	markers,	CD34	analysis	was	reported	in	5	
studies19‐23;	Fernández	et	al	studied	CD31	and	Chuang	et	al	stud‐
ied	 CD105.24,25	 Factor	 VIII	 was	 evaluated	 in	 2	 studies.26,27	 For	
LVD	markers,	D2‐40	was	evaluated	in	3	studies28‐30	and	LYVE‐1	
was	reported	 in	2	studies.21,31	The	end‐point	measurement	was	
reported	as	OS	in	4	studies.19,22,29,31	In	addition,	the	outcome	was	
also	reported	as	PFS,20	DFS,21,25,28	DSS,24,27,30	RFS,26	and	tumor‐
specific	survival.23
3.2 | Risk of bias results
Based	 on	 the	 MAStARI	 evaluation	 tool,	 the	 risk	 of	 bias	 in	 the	
included	articles	was	either	 low	 (n	=	9)	or	moderate	 (n	=	4).	The	
risk	of	bias	for	each	study	and	the	applied	questions	are	shown	in	
Table	S3.
3.3 | Preoperative treatments of the 
studied cohorts
As	 the	 preoperative	 treatment	 could	 impact	 the	 expression	 of	
MVD/LVD	 in	 the	 studied	 patient	 samples,	 we	 screened	 the	 in‐
cluded	 reports	 to	 extract	 any	 relevant	 data.	 The	 samples	 were	
not	subjected	to	any	sort	of	preoperative	treatments	in	a	total	of	
7	 studies.19‐22,25,29,31	 In	 one	 study	 from	 India,	 the	 patients	 were	
primarily	 treated	 by	 either	 surgery	 or	 radiotherapy.26	 Some	 of	
the	patients	who	underwent	surgery	were	also	given	adjuvant	ra‐
diotherapy,	 chemotherapy,	 or	 radiotherapy	 and	 chemotherapy.26 
However,	this	information	was	either	missing	or	not	clearly	stated	
in	the	other	5	studies.23,24,27,28,30
F I G U R E  1  Flow	chart	defining	the	
search	strategy	and	the	studies	included	
and	excluded	along	various	steps.	TSCC,	
tongue	squamous	cell	carcinoma
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3.4 | Microvessel density markers as 
prognosticators in TSCC
3.4.1 | Prognostic value of CD34
We	found	5	studies	that	analyzed	the	prognostic	value	of	CD34	 in	
TSCC	patients.	Huang	et	al19	did	not	find	a	statistically	significant	cor‐
relation	between	MVD	(determined	by	CD34)	and	OS	in	a	cohort	of	
80	TSCC	patients.	This	was	similar	to	the	results	of	Toyoda	et	al,20 
who	 reported	no	 significant	 correlation	between	CD34	expression	
and	OS	or	PFS	in	a	similar	sample	size	(n	=	85).	In	contrast,	Sasahira	
et	al21	revealed	that	high	CD34	expression	was	associated	with	poor	
prognosis	and	reduced	DFS	when	they	analyzed	101	TSCC	patients	
(P = .0249).	Similarly,	Shao	et	al22	reported	a	significantly	reduced	OS	
in	TSCC	patients	(n	=	59)	with	high	CD34	expression	compared	with	
those	with	low	or	moderate	expression.	In	an	older	study	of	Forootan	
et	 al,23	 the	CD34‐expressing	vessel	 count	 (VC)	was	not	 associated	
with	 the	 growth	pattern	or	metastasis	 in	 a	 cohort	 of	51	TSCC	pa‐
tients.	However,	 the	Cox	proportional	hazards	model	 revealed	that	
patients	with	a	low	VC	tended	to	have	a	good	prognosis	(P = .023).	
Characteristics	of	the	studies	on	CD34	are	summarized	in	Table	1.
3.4.2 | Prognostic value of CD31 and CD105
We	found	only	one	study	that	used	CD31	to	correlate	MVD	and	the	
prognosis	 of	 43	 patients	 with	 TSCC.24	 In	 this	 small	 cohort	 study,	
Cox	regression	analysis	did	not	 indicate	tumor	vascularization	as	a	
prognostic	 factor	of	 survival	 (P = .59).	Chuang	et	 al25	 investigated	
the	expression	of	CD105	 in	94	TSCC	patients	 and	 found	 that	 the	
cumulative	5‐year	DFS	rates	of	patients	with	low	CD105	expression	
were	significantly	higher	than	those	with	high	expression	(P < .001).	
Moreover,	 Cox	 regression	 analysis	 showed	 that	 the	 expression	 of	
CD105	was	an	independent	factor	from	other	variables	for	survival	
(relative	 risk	8.0;	 95%	CI,	 2.525‐25.839;	P < .001).	Characteristics	
of	the	studies	regarding	these	2	markers	are	summarized	in	Table	2.
3.4.3 | Prognostic value of FVIII
A	series	of	84	TSCC	cases	were	enrolled	in	a	study	by	Vora	et	al.26 The 
authors	considered	a	mean	of	the	number	of	microvessels	from	3	vas‐
cular	hot	spots	as	representing	the	microvessel	count	for	each	patient.	
Early	stage	(stage	I	and	II)	cancer	patients	with	FVIII	greater	than	0.0	
were	 significantly	 associated	 with	 reduced	 OS	 and	 RFS.	 However,	
FVIII	lost	its	prognostic	significance	when	a	general	linear	model	was	
applied.26	 In	the	other	study,	Kantola	et	al27	reported	no	association	
between	FVIII	and	the	survival	rate	in	a	cohort	of	105	TSCC	patients.	
Further	information	is	summarized	in	Table	3.
3.5 | Lymphatic vessel density markers as 
prognosticators in TSCC
3.5.1 | Prognostic value of D2‐40
Al‐Shareef	 et	 al28	 revealed	 a	 strong	 correlation	 between	 D2‐40	
and	 LN	 metastasis	 in	 80	 TSCC	 patients.	 Both	 OS	 and	 DFS	 were	
associated	with	intra‐	and	peritumoral	LVD,	as	patients	with	a	high	
LVD	had	a	poor	prognosis	with	 a	high	possibility	of	 recurrence.	A	
significant	reduction	in	OS	was	observed	by	Yan	et	al29	in	80	TSCC	
cases	associated	with	high	D2‐40,	which	also	indicated	higher	nodal	
metastasis.	 In	 the	61	cases	 analyzed	by	Seppälä	et	 al,30	 the	mean	
LVD	did	not	 influence	patient	 survival.	However,	 the	 relative	den‐
sity	 of	 lymphatic	 vessels	 (RDLV)	was	 significantly	 associated	with	
poor	OS	(P = .004)	 in	TSCC	patients.	The	authors	calculated	RDLV	
by	dividing	the	mean	number	of	D2‐40+	LVD	by	the	mean	number	of	
von	Willebrand	factor+	LVD	per	microscopic	field.	These	studies	are	
summarized	in	Table	4.
3.5.2 | Prognostic value of LYVE‐1
Ding	et	al31	evaluated	the	prognostic	value	of	LYVE‐1	in	50	cases	and	
revealed	 fewer	 intratumoral	 LYVE‐1+	 vessels	 than	peritumoral	 ves‐
sels.	Moreover,	they	did	not	observe	a	significant	correlation	between	
LYVE‐1	and	OS	of	TSCC	patients.	In	contrast,	Sasahira	et	al21 revealed 
that	LVD	positive	for	LYVE‐1	showed	a	poor	association	with	DFS	in	
101	TSCC	patients.	 In	addition,	high	LVD	was	associated	with	poor	
prognosis	(P < .0001).	Both	studies	are	summarized	in	Table	5.
4  | DISCUSSION
Angiogenesis	and	lymphangiogenesis	promote	cancer	cell	growth	and	
metastasis.14	Metastasis	 is	 estimated	 to	 be	 responsible	 for	 approxi‐
mately	90%	of	 cancer‐associated	deaths.32	TSCC	 is	one	of	 the	most	
common	 intraoral	 cancers	 and	 is	 characterized	 by	 an	 extensive	 and	
well‐developed	vascular	and	lymphatic	system	and	a	high	rate	of	cer‐
vical	LN	metastasis.33	Therefore,	identification	of	biomarkers	that	as‐
sociate	with	TSCC	progression	and	metastasis,	such	as	MVD	and	LVD,	
could	enhance	prognostic	and	therapeutic	approaches.	In	the	present	
study,	several	MVD	and	LVD	markers	were	reviewed	in	13	clinical	stud‐
ies	that	 involved	a	total	of	973	TSCC	patients.	Only	7	of	the	eligible	
13	studies	(53.84%)	indicated	a	prognostic	significance	of	one	or	more	
of	the	studied	MVD	or	LVD	markers.	The	results	of	almost	all	mark‐
ers	were	 controversial.	However,	 studies	 on	D2‐40	 suggested	 some	
promising	results.	The	use	of	these	MVD	and	LVD	markers	cannot	be	
recommended	for	clinical	use	at	this	time	and	more	studies	(especially	
on	D2‐40)	are	needed	with	a	larger	number	of	TSCC	cases.
Several	reports	indicate	that	CD34	can	be	used	as	a	specific	and	
sensitive	biomarker	in	hepatocellular	carcinoma	and	lung	cancer	and	
could	 therefore	 become	 an	 integral	 part	 of	 a	more	 reliable	 staging	
system.34‐36	 Moreover,	 the	 use	 of	 CD34	 as	 an	 angiogenic	 marker	
was	 superior	 to	other	markers	as	 it	 yielded	better	 results	with	 less	
background	and	makes	quantification	easier.23	 In	TSCC,	 the	 vascu‐
lar	hot	spots	were	also	positively	correlated	with	tumor	size;	multi‐
variate	analysis	showed	better	prognosis	in	patients	with	low	CD34	
expression.23	Additionally,	Sasahira	et	al21	showed	that	higher	CD34	
expression	strongly	correlated	with	poor	survival.	It	was	also	reported	
by	Shao	et	al22	that	CD34	positively	correlated	to	VEGF	and	to	poor	
survival	of	TSCC	patients.	This	reflects	the	key	role	of	VEGF	in	the	
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development	of	a	functional	vascular	system	in	the	tumor	microen‐
vironment.	However,	 two		 later	studies	were	not	able	to	reproduce	
the	significance	of	CD34	as	a	prognostic	marker	in	TSCC	patients.19,20
CD31	 (platelet	 endothelial	 cell	 adhesion	 molecule	 1),	 CD105	
(endoglin),	FVIII,	 and	von	Willebrand	 factor	are	other	blood	vessel	
markers.	Even	though	CD31,	FVIII,	and	CD105	are	determinants	of	
MVD,	it	was	concluded	that	CD105	expression	is	the	best	angiogenic	
marker	and	significant	prognosticator	of	DFS	in	non‐small	cell	 lung	
cancer	patients.37	Moreover,	 several	 reports	have	found	a	positive	
correlation	between	CD105+	MVD	and	cancer	cell	metastasis,	includ‐
ing	in	HNSCC	patients.38,39	Advanced	oral	cancer	stages	correlated	
with	higher	expression	of	CD105.40	CD31	and	CD105	have	thus	far	
been	studied	only	once	 in	TSCC	patients.	Although	the	expression	
of	CD105	was	reported	to	be	an	independent	prognostic	factor	for	
survival	 by	 multivariate	 analysis	 according	 to	 the	 Cox	 regression	
model,25	prognostic	value	was	not	found	when	CD31	was	assessed.	
This	might	be	due	to	the	small	sample	size	in	their	study.24 There are 
two	studies	of	FVIII	in	TSCC	that	reported	contradictory	results.26,27
D2‐40	(podoplanin),	a	mucin‐type	transmembrane	glycoprotein,	is	
preferentially	expressed	in	lymphatic	endothelial	cells	and	is	considered	
a	specific	marker	for	the	lymphatic	endothelium.30,41	The	tumorigenic	
role	of	podoplanin	has	been	suggested	in	several	reports	based	on	its	
high	expression	in	potentially	malignant	lesions	such	as	oral	leukoplakia,	
oral	carcinoma	in	situ,	and	oral	squamous	cell	carcinoma.42,43	The	TSCC	
samples	with	high	D2‐40+	LVD	expression	showed	significant	prognos‐
tic	value	in	two	studies.28,29	Although	LVD	did	not	produce	a	significant	
correlation	with	patient	survival	 in	the	third	study,	RDLV	was	instead	
significantly	 associated	 with	 poor	 OS	 in	 TSCC	 patients.30	 However,	
these	results	should	be	confirmed	with	studies	in	a	larger	patient	cohort.
Lymphatic	 vessel	 endothelial	 hyaluronan	 receptor‐1	 is	 another	
specific	marker	for	lymphatic	endothelium.44	A	significant	relationship	
was	found	between	intratumoral	LVD	expression	and	LN	metastasis	in	
HNSCC.45	In	another	study,	Beasley	et	al46	revealed	discrete	hot	spots	
of	 intratumoral	LYVE‐1+	 lymphatics	 in	all	HNSCC	cases,	which	were	
associated	with	cervical	LN	 involvement.	Consistent	with	this,	 intra‐
tumoral	LYVE‐1+	LVD	in	97	primary	HNSCC	tumors	increased	risk	for	
local	relapse	and	indicated	poor	disease‐specific	prognosis.47	In	a	study	
by	Sasahira	et	al,21	LYVE‐1+	LVD	were	found	at	the	edges	of	the	TSCC	
tissues	and	the	vessels	were	irregular	in	shape,	and	when	accompanied	
with	high	VEGF	showed	shorter	DFS.	In	a	later	study	by	Ding	et	al,31 
there	was	no	correlation	between	the	expression	of	neither	 intratu‐
moral	nor	peritumoral	LYVE‐1	and	the	survival	of	patients	with	TSCC.
In	 conclusion,	 although	 the	 evidence	 reported	 in	 this	 review	
suggests	 that	 increased	 expression	 of	MVD	or	 LVD	markers	 for	
TSCC	patients	could	be	associated	with	reduced	survival,	there	is	
currently	 insufficient	evidence	to	recommend	 implementation	of	
any	of	these	markers	as	part	of	a	reliable	staging	system	in	clinical	
practice.	This	 is	due	to	several	 factors,	such	as	 the	small	patient	
cohorts	of	the	studies,	different	assessment	criteria	used	for	MVD	
and	LVD	markers,	the	heterogeneity	of	the	study	samples	(mixing	
either	 base	 of	 the	 tongue	 “posterior	 1/3”,	 oral	 tongue	 “anterior	
2/3,”	 or	 total	 tongue	 cancer	 for	 the	 analysis),	 and	 the	 absence	
of	HR	and	CI	information	in	the	majority	of	the	studies	(11	of	13	T
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studies).	Overall,	this	review	highlights	the	need	for	more	accurate	
prognostic	studies	on	TSCC.
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